
News|Articles|March 1, 2005
Exenatide: A novel incretin mimetic hormone for the treatment of type 2 diabetes
A number of clinical approaches are utilized in managing the overlapping aspects of poor glycemic control in patients with type 2 diabetes. Exenatide (Amylin/Lilly), a novel drug in a new medication class known as the incretin mimetic agents, offers a new mechanism to achieve glycemic control.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Overlooked bladder nerves now thought to reduce UTI burden through pain signaling, study shows
2
Real-World Usage of Biologics in Psoriatic Arthritis
3
Researchers discover new pathway to fight liver inflammation
4
Medicare beneficiaries are paying more for price-negotiated drugs, survey finds
5





















